Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia.

Find People
Find Everything
About This Site
Edit My Profile
Login to Profiles
DIRECT2Experts
Help / FAQ

History

Co-Investigator

Elastofibromatous Chan

Parvovirus B19 myocard

Radiological features

Emergence of polyclona

See All (6) pages

Announcement

You can now add alternative names! Click here to add other names that you've published under.

Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia.

Baker SD, Zimmerman EI, Wang YD, Orwick S, Zatechka DS, Buaboonnam J, Neale GA, Olsen SR, Enemark EJ, Shurtleff S, Rubnitz JE, Mullighan CG, Inaba H. Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia. Clin Cancer Res. 2013 Oct 15; 19(20):5758-68.

View in: PubMed

subject areas

Adolescent
Alleles
Animals
Antineoplastic Agents
Cell Line, Tumor
Child
Drug Resistance, Neoplasm
Female
fms-Like Tyrosine Kinase 3
Humans
Indoles
Leukemia, Myeloid, Acute
Male
Mice
Models, Molecular
Molecular Conformation
Mutation
Niacinamide
Phenylurea Compounds
Protein Binding
Protein Interaction Domains and Motifs
Protein Kinase Inhibitors
Pyrroles
Treatment Outcome

authors with profiles

Eric Enemark